Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.

Pharmacogenomics - 1 Jun 2016

Jamaluddin Jazlina Liza, Huri Hasniza Zaman, Vethakkan Shireene Ratna

Abstract excerpt

AIM: To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS: DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 inhibitors sitagliptin, vildagliptin or linagliptin. Genotyping was performed by Applied Biosystems TaqMan SNP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Diastole

Share to Genotype

Share to Glycated Hemoglobin

Share to Potassium Channels, Inwardly Rectifying

Share to Triglycerides

Source

Identifiers

PMID: 27249660
DOI: 10.2217/pgs-2016-0010

Genes

KCNJ11
DBP
DPP4
WFS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.PMID 27249660Read ↗

Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes.Semantic proximity Read ↗

Genetic Variants Identified from GWAS for Predisposition to Type 2 Diabetes Predict Sulfonylurea Drug Response.Semantic proximity Read ↗

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.Semantic proximity Read ↗

Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 DiabetesSemantic proximity Read ↗

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Semantic proximity Read ↗

Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.Semantic proximity Read ↗

Pharmacogenetics of Oral Antidiabetic DrugsSemantic proximity Read ↗

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.Semantic proximity Read ↗

Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes.Semantic proximity Read ↗

Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors.Semantic proximity Read ↗

Pharmacogenetics and target identification in diabetes.Semantic proximity Read ↗

Adiponectin gene polymorphism rs2241766 T/G is associated with response to pioglitazone treatment in type 2 diabetic patients from southern China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.